TRI-LEGEST FE Drug Patent Profile
✉ Email this page to a colleague
When do Tri-legest Fe patents expire, and when can generic versions of Tri-legest Fe launch?
Tri-legest Fe is a drug marketed by Barr and is included in one NDA.
The generic ingredient in TRI-LEGEST FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
Summary for TRI-LEGEST FE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TRI-LEGEST FE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for TRI-LEGEST FE
US Patents and Regulatory Information for TRI-LEGEST FE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Barr | TRI-LEGEST FE | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-28 | 076105-001 | Oct 26, 2007 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |